By Nana O 
A significant advancement in the fight against glioblastoma, a notoriously aggressive brain tumor with a grim prognosis, has emerged from research led by Keck Medicine of USC. A novel therapeutic approach, combining Tumor Treating Fields (TTFields) with immunotherapy and chemotherapy, has demonstrated the potential to not only halt tumor growth but also to significantly extend survival rates for patients. The National Brain Tumor Society reports that the average survival for individuals diagnosed with glioblastoma is a mere eight months, underscoring the urgent need for more effective treatment strategies. This new research offers a beacon of hope, suggesting a paradigm shift in how this devastating disease might be managed.
The Science Behind the Breakthrough: TTFields and Immune System Synergy
The cornerstone of this promising new treatment lies in the innovative application of Tumor Treating Fields (TTFields) therapy. This technology utilizes targeted, low-intensity alternating electric fields delivered directly to the tumor site. The mechanism of action is multifaceted: TTFields disrupt the fundamental cellular processes that drive tumor proliferation by creating an oscillating electrical environment that impedes the division and migration of cancer cells. Crucially, beyond directly inhibiting tumor growth, TTFields also play a vital role in activating the body’s own immune system to recognize and attack cancerous cells.
In the context of glioblastoma, TTFields are delivered through a specialized set of mesh electrodes applied to the scalp. These electrodes are strategically positioned to generate precise electric fields, tuned to a specific frequency and intensity, that are focused on the tumor. Patients typically wear these electrodes for approximately 18 hours a day, a commitment that allows for continuous therapeutic intervention.
The research team observed a particularly compelling effect when TTFields were combined with immunotherapy, specifically the immune checkpoint inhibitor pembrolizumab, and the standard chemotherapy agent temozolomide. The study revealed that TTFields act as a powerful immune modulator, attracting a greater number of tumor-fighting T cells – crucial components of the adaptive immune system responsible for identifying and neutralizing malignant cells – into and around the glioblastoma. This influx of T cells sets the stage for a more robust anti-cancer response.
"By using TTFields with immunotherapy, we prime the body to mount an attack on the cancer, which enables the immunotherapy to have a meaningful effect in ways that it could not before," explained David Tran, MD, PhD, chief of neuro-oncology with Keck Medicine, co-director of the USC Brain Tumor Center, and corresponding author of the study. "Our findings suggest that TTFields may be the key to unlocking the value of immunotherapy in treating glioblastoma."
Addressing the Glioblastoma Immune Privilege
Glioblastoma presents a unique challenge due to the brain’s inherent immune privilege, a protective state that shields the central nervous system from inflammatory responses. This is partly mediated by the blood-brain barrier (BBB), a highly selective physiological barrier that regulates the passage of substances from the bloodstream into the brain. While essential for protecting the brain from toxins and pathogens, the BBB can also impede the entry of therapeutic agents, including immune cells and cancer-fighting drugs, into the tumor microenvironment.
Consequently, glioblastomas often exist in an immunosuppressive environment, characterized by a scarcity of tumor-infiltrating lymphocytes, particularly T cells. This scarcity significantly diminishes the efficacy of immunotherapies that rely on a robust T cell presence to initiate and sustain an anti-cancer response. Traditional chemotherapy, while a mainstay in cancer treatment, also faces limitations in penetrating the BBB and overcoming the tumor’s defense mechanisms.
The breakthrough observed in this study lies in TTFields’ ability to overcome this immune evasion. By drawing T cells into the tumor microenvironment, TTFields effectively create an "in situ immunization," essentially kick-starting an immune reaction directly within the tumor itself. This is a critical step that then allows immunotherapies like pembrolizumab to exert their full potential.
Dr. Tran elaborated on this concept using an analogy: "Think of it like a team sport — immunotherapy sends players in to attack the tumor (the offense), while TTFields weaken the tumor’s ability to fight back (the defense). And just like in team sports, the best defense is a good offense." This synergistic approach amplifies the body’s natural defenses, transforming a previously challenging landscape for immunotherapy into a fertile ground for cancer cell destruction.
Clinical Trial Insights and Survival Data
The research team analyzed data from the 2-THE-TOP Phase 2 clinical trial, which enrolled 31 patients newly diagnosed with glioblastoma who had already completed chemoradiation therapy. The core of the study focused on a cohort of 26 patients who received TTFields in conjunction with both chemotherapy and immunotherapy. A particularly high-risk subgroup within this cohort consisted of seven patients with inoperable tumors due to their critical locations, a demographic typically facing the bleakest prognoses and limited therapeutic options.
Patients in the trial received a regimen that included six to 12 monthly cycles of chemotherapy, administered alongside TTFields for up to 24 months. The duration and frequency of these treatments were tailored to each patient’s individual response. Immunotherapy, specifically pembrolizumab, was administered every three weeks, commencing with the second dose of chemotherapy, and continuing for up to 24 months.
The results were striking. Patients who received the combination therapy of TTFields, chemotherapy, and immunotherapy demonstrated a significant improvement in survival compared to historical data of patients treated with TTFields and chemotherapy alone. The study reported an approximate 10-month increase in overall survival for patients in this combined treatment arm.
Furthermore, a particularly compelling observation emerged from the subgroup of patients with larger, unresected (not surgically removed) tumors. These patients, who would typically be considered to have a poorer outlook, exhibited an even more pronounced immune response to the TTFields therapy and experienced an even greater survival benefit, living approximately 13 months longer. This finding suggests that the presence of a larger tumor mass might, counterintuitively, provide more targets for the TTFields to engage with, thereby amplifying the initial immune activation.
"Further studies are needed to determine the optimal role of surgery in this setting, but these findings may offer hope, particularly for glioblastoma patients who do not have surgery as an option," stated Dr. Tran, highlighting the potential impact of this therapy for patients where surgical intervention is not feasible.
A Look at the Numbers: Quantifying the Impact
The implications of this research are substantial, particularly when viewed against the backdrop of glioblastoma’s historically poor outcomes. The observed 70% increase in overall survival, as indicated by the study’s findings when immunotherapy is added to the TTFields and chemotherapy regimen, represents a significant leap forward. To put this into perspective, consider that a 70% increase on an average survival of eight months translates to an additional 5.6 months of life, bringing the potential average survival closer to 13.6 months. While this still represents a challenging prognosis, it marks a critical step in improving patient outcomes.
The enhanced immune response in patients with larger, unresected tumors is another key quantitative finding. These patients not only lived longer but also demonstrated substantially stronger immune activation compared to patients who underwent surgical removal of their tumors. This suggests that the TTFields’ ability to prime the immune system might be particularly potent when there is a substantial tumor burden to target.
The Journey from Discovery to Clinical Application: A Timeline of Progress
The development of TTFields therapy has been a gradual but persistent endeavor, with research into its applications for various cancers spanning over a decade. David Tran, MD, PhD, has been a leading figure in this research, dedicating significant effort to understanding and optimizing the use of TTFields. The current study builds upon years of preclinical research and earlier clinical trials that have explored the efficacy of TTFields in combination with standard treatments for glioblastoma.
The transition from Phase 2 trials, like the 2-THE-TOP study, to larger, more definitive Phase 3 trials is a crucial step in validating new therapeutic approaches. Keck Medicine is actively involved in such a multicenter Phase 3 clinical trial, designed to rigorously assess the efficacy of TTFields in combination with immunotherapy and chemotherapy on a broader scale. Dr. Tran is serving as the chair of the steering committee for this pivotal trial, demonstrating his continued commitment to advancing this research. Frances Chow, MD, a neuro-oncologist at USC Norris, is the principal investigator at the Keck Medicine study site.
This Phase 3 trial, a collaborative effort involving 28 sites across the United States, Europe, and Israel, aims to enroll over 740 patients by April 2029. The trial’s design is comprehensive, including patients with varying degrees of tumor resection – gross total resection, partial resection, or biopsy-only tumors. This approach is intended to thoroughly evaluate how the extent of surgical tumor removal influences the immune response when TTFields, immunotherapy, and chemotherapy are administered. Such detailed investigation is vital for refining treatment protocols and maximizing patient benefit.
Broader Implications and Future Directions
The implications of this research extend beyond the immediate treatment of glioblastoma. If further studies confirm these promising findings, the combination of TTFields with immunotherapy could revolutionize the management of other challenging brain tumors and potentially other cancer types that have historically resisted immune-based therapies. The ability to effectively "prime" the tumor microenvironment for an immune attack could unlock new therapeutic avenues for a wide range of malignancies.
The study’s funding by Novocure, the manufacturer of the Optune device used for TTFields, and Dr. Tran’s consultative role with the company, highlight the collaborative nature of translational research. This partnership is instrumental in moving promising laboratory discoveries into clinical practice. The patent applications filed by Dr. Chen and Dr. Tran related to this work further underscore the innovative nature of their contributions.
The scientific community will be closely watching the progress of the ongoing Phase 3 trial. The results from this large-scale study will be critical in determining whether this novel combination therapy becomes a standard of care for glioblastoma patients. The possibility of offering improved survival and quality of life to individuals facing this devastating diagnosis represents a significant triumph for medical science and a profound source of hope for patients and their families worldwide. The research undertaken at Keck Medicine of USC is at the forefront of this critical medical advancement, pushing the boundaries of what is possible in the fight against brain cancer.
